Santarus Announces FDA Acceptance Of New Drug Application For ZEGERID Tablet Product
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for a new tablet formulation to add to its ZEGERID® family of branded prescription pharmaceutical products. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Santarus expects the FDA will complete its review or otherwise respond to the NDA by December 4, 2009.
More: continued here
Filed under: Acid Reflux/GERD on April 7th, 2009
You must be logged in to post a comment.